TABLE 1.
Baseline Characteristics of Patients in the Study According to Obesity
| Variables | Before Matching | After Matching | ||
|---|---|---|---|---|
| Obese (n = 1,335) | Nonobese (n = 5,089) | Obese (n = 1,335) | Nonobese (n = 1,335) | |
| Age | 70 (60–78) | 73 (62–81)a | 70 (60–78) | 70 (60–79) |
| Male | 699 (52.4) | 3,090 (60.7)a | 699 (52.4) | 726 (54.4) |
| Body mass index, kg/m2 | 27.1 (26–29.1) | 20.6 (18.4–22.5)a | 27.1 (26–29.1) | 20.9 (18.8–22.8)a |
| Comorbidities | ||||
| Cardiovascular disease | 339 (25.4) | 1,298 (25.5) | 339 (25.4) | 323 (24.2) |
| Diabetes | 566 (42.4) | 1,748 (34.3)a | 566 (42.4) | 517 (38.7) |
| Chronic lung disease | 194 (14.5) | 862 (16.9)b | 194 (14.5) | 181 (13.6) |
| Chronic kidney disease | 214 (16.0) | 730 (14.3) | 214 (16.0) | 225 (16.9) |
| Chronic liver disease | 153 (11.5) | 531 (10.4) | 153 (11.5) | 151 (11.3) |
| Solid malignancy | 439 (32.9) | 1,922 (37.8)c | 439 (32.9) | 456 (34.2) |
| Hematological malignancy | 110 (8.2) | 359 (7.1) | 110 (8.2) | 104 (7.8) |
| Connective tissue disease | 24 (1.8) | 131 (2.6) | 24 (1.8) | 29 (2.2) |
| Chronic neurologic disease | 250 (18.7) | 1,179 (23.2)c | 250 (18.7) | 256 (19.2) |
| Charlson comorbidity index | 5 (4–7) | 6 (4–7)c | 5 (4–7) | 5 (4–7) |
| Clinical Frailty Score | 4 (3–6) | 5 (3–7)a | 4 (3–6) | 4 (3–7) |
| Eastern Cooperative Oncology Group performance status | 1 (1–3) | 2 (1–3)a | 1 (1–3) | 2 (1–3) |
| Sequential Organ Failure Assessment | 6 (4–8) | 6 (4–8) | 6 (4–8) | 6 (4–8) |
| Septic shock | 257 (19.3) | 1,093 (21.5) | 257 (19.3) | 276 (20.7) |
| ICU admission | 711 (53.3) | 2,264 (44.5)a | 711 (53.3) | 723 (54.2) |
| Laboratory variables | ||||
| Lactate level, mmol/L | 2.6 (1.5–4.6) | 2.6 (1.5–4.7) | 2.6 (1.5–4.6) | 2.6 (1.6–4.8) |
| C-reactive protein, mg/dL | 11.0 (4.3–20.2) | 11.1 (4.7–19.1) | 11.0 (4.3–20.2) | 11.5 (4.5–20.0) |
| Primary site of infection | ||||
| Pulmonary | 411 (30.8) | 2,292 (45.0) | 411 (30.8) | 465 (34.8) |
| Abdominal | 454 (34.0) | 1,348 (26.5) | 454 (34.0) | 429 (32.1) |
| Urinary | 237 (17.8) | 715 (14.0) | 237 (17.8) | 231 (17.3) |
| Skin or soft tissue | 72 (5.4) | 142 (2.8) | 72 (5.4) | 49 (3.7) |
| Catheter related | 11 (0.8) | 43 (0.8) | 11 (0.8) | 13 (1.0) |
| Neurologic | 10 (0.7) | 28 (0.6) | 10 (0.7) | 6 (0.4) |
| Systemic infections without a primary site | 140 (10.5) | 521 (10.2) | 140 (10.5) | 142 (10.6) |
| Type of infection | ||||
| Community acquired | 1,003 (75.1) | 4,034 (79.3)c | 1,003 (75.1) | 997 (74.7) |
| Nosocomial | 332 (24.9) | 1,055 (20.7) | 332 (24.9) | 338 (25.3) |
| Multidrug-resistant organism | 314 (23.5) | 1,148 (22.6) | 314 (23.5) | 306 (22.9) |
| Combination antibiotic therapy | 790 (59.6) | 3,168 (62.6)b | 790 (59.6) | 827 (62.4) |
| Adequate antimicrobial therapy | 1,188 (89.0) | 4,490 (88.2) | 1,188 (89.0) | 1,178 (88.2) |
| Source control of sepsis | 208 (15.6) | 625 (12.3)c | 208 (15.6) | 207 (15.5) |
| Adjunctive corticosteroid therapy | 255 (19.1) | 891 (17.5) | 255 (19.1) | 265 (19.9) |
a
p < 0.001,
b
p < 0.05,
c
p < 0.01.
Data are presented as median (interquartile range) or number (%).